苏比努尔·艾尔肯, 李静. 原发性IgA肾病的靶向治疗进展[J]. 临床肾脏病杂志, 2023, 23(1): 74-78. DOI: 10.3969/j.issn.1671-2390.2023.01.013
    引用本文: 苏比努尔·艾尔肯, 李静. 原发性IgA肾病的靶向治疗进展[J]. 临床肾脏病杂志, 2023, 23(1): 74-78. DOI: 10.3969/j.issn.1671-2390.2023.01.013
    Subinur Elken, Li Jing. Recent advances in targeted therapy of primary IgA nephropathy[J]. Journal of Clinical Nephrology, 2023, 23(1): 74-78. DOI: 10.3969/j.issn.1671-2390.2023.01.013
    Citation: Subinur Elken, Li Jing. Recent advances in targeted therapy of primary IgA nephropathy[J]. Journal of Clinical Nephrology, 2023, 23(1): 74-78. DOI: 10.3969/j.issn.1671-2390.2023.01.013

    原发性IgA肾病的靶向治疗进展

    Recent advances in targeted therapy of primary IgA nephropathy

    • 摘要: IgA肾病(immunoglobulin A nephropathy,IgAN)已成为威胁中国居民生命健康的重大疾病。目前针对该病的治疗主要是支持疗法和免疫抑制治疗,免疫抑制治疗对患者的毒副作用大,因此药物的选择性和安全性是治疗IgAN的关键,基于对IgAN自身免疫发病机制的不断理解,出现了多种药理治疗的靶点,包括免疫反应、黏膜免疫、肾脏炎症和补体激活等。本文基于IgAN的发病机制,对IgAN靶向治疗的最新进展进行综述。

       

      Abstract: IgA nephropathy(IgAN) has become a major disease threatening the quality-of-life of Chinese residents.Currently the treatment of this disease is mainly supportive and immunosuppressive therapy.Immunosuppressive therapy is associated with many side effects.Therefore the selectivity and safety of drugs are essential for treating IgAN.Based on the continuous understanding of autoimmune pathogenesis of IgAN, many targets are available for drug therapy, including immune response, mucosal immunity, renal inflammation and complement activation.Based on the pathogenesis of IgAN, this review summarized the latest advances of IgAN targeted therapy.

       

    /

    返回文章
    返回